


Amendments to the Claims

Listing of the Claims:

Claims 1-12 (canceled).

Claim 13 (new): A method for the treatment or inhibition of a cancer expressing breast cancer resistance protein (BCRP) comprising administering imatinib of the formula I



(I)

or a pharmaceutically acceptable salt thereof.

Claim 14 (new): A method for the treatment of a cancer over-expressing breast cancer resistance protein (BCRP) comprising administering imatinib of formula I or a pharmaceutically acceptable salt thereof.

Claim 15 (new): A method to prevent or reverse resistance to an anticancer agent of a cancer that expresses BCRP in a human subject having said cancer comprising administering imatinib of formula I or a pharmaceutically acceptable salt thereof.

Claim 16 (new): A method to improve the absorption of an orally-administered anticancer agent comprising administering imatinib of formula I or a pharmaceutically acceptable salt thereof.

Claim 17 (new): A method to improve the absorption of an orally-administered anticancer agent by inhibiting BCRP in a patient having a cancer comprising administering imatinib of formula I or a pharmaceutically acceptable salt thereof.

Claim 18 (new): A method according to claim 13 wherein the anticancer agent is an anthracycline cytotoxic agent or a camptothecin-derived topoisomerase I inhibitor.

Claim 19 (new): A method according to claim 18 wherein the anticancer agent is selected from the group consisting of mitoxanthrone, doxorubicin, topotecan, irinotecan also referred as CTP-11, 7-ethyl-10-hydroxycamptothecin also referred as SN-38, 9-amino-camptothecin, 9-nitrocamptothecin, lurtotecan, diflomotecan, BAY38-3441, 7-(2-trimethylsilyl)ethylcamptothecin also referred as BNP1350, 10-hydroxy-7-t-butyltrimethylsilylcamptothecin also referred as DB67, CT2016, DE310, T-0128 and PROTHERCAN.

Claim 20 (new): A method according to claim 19 wherein the anticancer agent is selected from the group consisting of topotecan, irinotecan, SN-38, mitoxanthrone and doxorubicin.

Claim 21 (new): A method according to claim 13 wherein imatinib is in the form of the mesylate salt.

Claim 22 (new): A method of treating a cancer that expresses BCRP in a human subject, which comprises administering a therapeutically effective amount of an anticancer agent and an effective BCRP-inhibiting amount of imatinib or a pharmaceutically acceptable salt thereof.

Claim 23 (new): A method according to claim 13 wherein the cancer is selected from the group comprising colon cancer, breast cancer, liver cancer, ovarian cancer, fibrosarcoma, myeloma, acute myeloid leukemia (AML), gastric cancer and non-small cell lung cancer